Globus' sales soar in Q2; Hologic wins FDA nod for imaging tech;

@FierceMedDev: Trending on FierceMedicalDevices.com: Covidien watches profits slide after kicking drugs. Article | Follow @FierceMedDev

@MarkHFierce: House Republican freshmen are pressing hard for a vote on a device tax repeal bill. Item | Follow @MarkHFierce

@DamianFierce: Now the Senate is getting in on the push to spare FDA user fees from sequester cuts. Story | Follow @DamianFierce

@MichaelGFierce: Trending on FierceDrugDelivery.com: Swedish team creates 'impossible' record-breaking drug delivery material. Article | Follow @MichaelGFierce

> Globus Medical ($GMED) hauled in $107 million in revenue last quarter, 11.5% above the same period last year. Results

> Ambry Genetics has launched sequencing-based renal, pancreatic and paraganglioma-pheochromocytoma cancer tests. News

> Hologic ($HOLX) picked up FDA clearance for its dual energy X-ray absorptiometry femur exam. More

> Illumina's ($ILMN) Verinata Health became the first non-invasive prenatal test provider to win a clinical lab permit from the New York State Department of Health. Release

> Finnish outfit Biohit has launched a test that detect celiac disease, ditching endoscopy and using only fingertip blood. Article

> As concerns mount over how life sciences companies conduct themselves in China, Baxter ($BAX) revealed that it encountered bribery in one of its joint ventures there but has dealt with the issue internally. Report | More from FiercePharma

> Diagnostics developer Castle Biosciences notched more positive data for its DecisionDx-Melanoma test, demonstrating that the gene-expression assay is an effective tool for classifying which cancers will recur. Item

Biotech News

@FierceBiotech: Industry Voices: The Zero-Person Biotech Company. Item | Follow @FierceBiotech

@JohnCFierce: Biotech's IPO boom extends its streak through a blistering July. Report | Follow @JohnCFierce

@RyanMFierce: Didn't take the lawyers long to start fishing for angry Optimer shareholders after Cubist buyout announced Tuesday. Release | Follow @RyanMFierce

@EmilyMFierce: NIH team sees diabetes drug as a possible tool for extending life. Story | Follow @EmilyMFierce

> Survey: Americans say cancer should be top priority for medical research. Story

> Stem cell transplants show potential in patients with extremely rare brain disease. More

> Baxter caught up in China bribery scandal. Item

Pharma News

@FiercePharma: Tension rises for pharma in China as court reportedly fines J&J, officials visit Sanofi. ICYMI yesterday | Follow @FiercePharma

@CarlyHFierce: More bribery allegations in China, these ones against Baxter (and just now surfacing from last year). News | Follow @CarlyHFierce

> 'Brazil generics issue' costs Sanofi nearly as much as patent losses. News

> Indian challenge to GSK's Tykerb comes from Fresenius. Article

> Teva earnings come up short and path to future rockier than before. Story

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.